September 2024 - Page 22 of 156

NASDAQ Companies - September 27, 2024

Molecular Partners Announces Upcoming Top-Rated Oral Presentation on MP0712, a ²¹²Pb-labeled Radio-DARPin Therapeutic targeting DLL3 for Small Cell Lung Cancer co-developed with Orano Med, at EANM 2024

First RDT candidate MP0712 shows low kidney accumulation and high tumor uptake in preclinical models MP0712 treatment leads to strong […]

NASDAQ Companies - September 26, 2024

Cue Biopharma Announces Pricing of $12.0 Million Public Offering

BOSTON, Sept. 26, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of […]

NYSE Companies - September 26, 2024

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

ROCKVILLE, Md., Sept. 26, 2024 (GLOBE NEWSWIRE) — Theriva Biologics, Inc. (NYSE American: TOVX) (“Theriva” or the “Company”), a diversified […]

NYSE Companies - September 26, 2024

Paramount Gold Nevada Provides Details of Its Upcoming AGM

WINNEMUCCA, Nev., Sept. 26, 2024 (GLOBE NEWSWIRE) — Paramount Gold Nevada Corp. (NYSE American: PZG) (“Paramount” or the “Company”) is […]

NASDAQ Companies - September 26, 2024

Banzai Announces Closing of $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

SEATTLE, Sept. 26, 2024 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology […]

NASDAQ Companies - September 26, 2024

Provident Financial Holdings Announces Extension of September 2023 Stock Repurchase Plan

RIVERSIDE, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) — Provident Financial Holdings, Inc. (“Company”), NASDAQ GS: PROV, the holding company for […]

NASDAQ Companies - September 26, 2024

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company […]